Shots:

• The P-III trial involves assesing of Sarclisa (IV- 10mg/kg qw for four weeks) in combination with carfilzomib (20/56mg/m2- bid) and dexamethasone in 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries
• The study resulted in meeting its 1EP and resulted in the reduction of risk of disease progression or death with no new safety signals observed
• Sarclisa is a mAb involves binding with specific epitope on the CD38 receptor- currently evaluated in P-III in combination with standard treatments for multiple myeloma and has also received positive CHMP opinion in combination with pomalidomide + dexamethasone for 2L+ R/R MM

Click here to read full press release/ article | Ref: Sanofi | Image: Twitter